The new variant contains the E484K mutation found in variants first identified in South Africa and Brazil.
It is nicknamed "Eek" by some scientists for its apparent ability to evade natural immunity from previous COVID-19 infection and to reduce protection offered by current vaccines.
On Tuesday (April 6), the Covid-19 cases in Indonesia rose by 4,549 within one day to 1,542,516, with the death toll adding by 162 to 41,977, the Health Ministry shad announced.
According to the ministry, 4,296 more people were discharged from hospitals, bringing the total number of recovered patients to 1,385,973.
The virus has spread to all the country's 34 provinces.
Specifically, within the past 24 hours, West Java recorded 964 new cases, Central Java 651, Jakarta 487, East Java 295 and Bali 236.
Siti Nadia Tarmizi, a senior health ministry official, said on Tuesday that the one variant case had recovered and did not infect close contacts, adding that the vaccines currently available in Indonesia could withstand the mutation.
However, Herawati Sudoyo, deputy director for fundamental research at the government-funded Eijkman Institute, which specialises in medical molecular biology and biotechnology, said the vaccines' ability to withstand the mutation had yet to be determined.
The first case of the variant comes as the country prepares for a reduced supply of COVID-19 vaccines due to export curbs of AstraZeneca's shot imposed by manufacturer India to prioritise its domestic supplies.
Indonesia's health minister said on Monday only 20 million of the 30 million doses it had ordered for a March-April delivery were available due to the export curbs.
He called for the vaccination programme to be readjusted and prioritised for the elderly.
With around 1.54 million cases and 41,900 deaths so far, Indonesia has the highest caseload in Southeast Asia and one of the worst epidemics in Asia.
Its vaccination programme aims to inoculate 181 million people and is relying heavily on a vaccine developed by China's Sinovac due to shipment delays of the AstraZeneca vaccine. - Reuters